Welcome to our dedicated page for QHSLab SEC filings (Ticker: USAQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
QHSLab, Inc. filings document a Nevada digital health issuer with Section 12(g) common stock traded under USAQ and no registered national exchange listing. Recent Form 8-K reports furnish Regulation FD press-release disclosures on Integrated Service Program growth, Q-Connect assessment launches, unaudited financial updates, fiscal results, and governance initiatives.
The company's material-event filings also record capital-structure transactions, including private placements of common stock and warrants, promissory note modifications, partial conversions, note repurchases, debt cancellation, and related unregistered sales of equity securities. These disclosures outline how QHSLab reports its financing activity, outstanding note obligations, common-stock issuance, and balance-sheet simplification alongside its digital health operating updates.
QHSLab, Inc. filed a current report describing that, on January 26, 2026, it issued a press release with preliminary unaudited 2025 financial results. The release, furnished as Exhibit 99.1, highlights strong revenue growth, expanding margins, and significant debt reduction, indicating improved sales performance, profitability, and balance sheet strength for 2025.
The company states that this information is provided under Regulation FD and is furnished rather than filed, so it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC reports unless specifically referenced. QHSLab also notes that it uses its website and social media channels, along with press releases, to share business and financial information that may be considered material for investors.
QHSLab, Inc. entered into a Note Repurchase Agreement with MedScience Research Group, Inc. Under this deal, QHSLab repurchased, cancelled, and extinguished a promissory note originally issued on June 23, 2021 in the principal amount of $750,000. As of December 31, 2025, the outstanding principal and accrued interest on the note totaled $470,529.
In exchange for eliminating this debt, QHSLab issued 1,568,432 shares of its common stock, as directed by MedScience. The company states that its Chief Executive Officer, who is a minority shareholder and service provider to MedScience, did not receive any personal distribution or other consideration from the transaction. The note is now fully satisfied and of no further force or effect.
The company characterizes this transaction as simplifying its capital structure, removing a related-party debt obligation, and improving the clarity of its balance sheet and financial reporting. The shares were issued in a private, unregistered offering under Section 4(a)(2) and/or Regulation D of the Securities Act as non-cash consideration for cancellation of indebtedness.
QHSLab, Inc. reported that it issued a press release on January 16, 2026 announcing that it has initiated a board expansion process intended to strengthen corporate governance and support its next phase of growth. The press release is furnished as Exhibit 99.1 under a Regulation FD disclosure item and is not deemed filed for liability purposes or automatically incorporated into other SEC documents.
The company also reminds investors that it uses its website and social media accounts on Twitter, LinkedIn, Facebook, and Instagram, along with press releases, to share public information that could be considered material. The filing’s exhibit index lists the board expansion press release and the cover page interactive data file.
QHSLab, Inc. furnished an update under Regulation FD by issuing a press release titled “QHSLab (OTCQB:USAQ) Issues Unaudited Financial and Operational Update Ahead of January 2026 Investor Session.” The press release is attached as Exhibit 99.1 and incorporated by reference.
The company states that the information in the press release is furnished, not filed, under the Exchange Act and is not automatically incorporated into other filings unless specifically referenced. QHSLab also emphasizes its use of its website and social media channels, including Twitter, LinkedIn, Facebook, and Instagram, as additional ways to share business and financial information that may be considered material.
QHSLab, Inc. entered into a promissory note modification and partial conversion agreement with Alex Mirakian MD PA, converting $126,548 of principal and accrued interest into 421,827 common shares at an effective price of $0.30 per share. This reduced the outstanding balance on the original 10% convertible note to $20,000 and extended its maturity date to December 31, 2026. The remaining balance is still convertible at the holder’s option at a price equal to the greater of a 25% discount to the 15‑day average market price or $0.50 per share, and the company may prepay it at any time without penalty. The shares were issued as restricted securities in a private transaction relying on Section 4(a)(2) and Rule 506 of Regulation D, with no underwriters or commissions involved.
QHSLab, Inc. disclosed that on December 26, 2025 it closed a private placement with two accredited investors for approximately $500,000 of common stock and warrants. The company issued 1,666,663 shares of common stock at $0.30 per share and 416,666 warrants to purchase common stock.
Each warrant is exercisable at $0.60 per share and expires on December 31, 2030. Net proceeds to QHSLab were in excess of $495,000, with planned use for general corporate purposes, including working capital. The securities were issued in a private offering relying on Regulation D exemptions and were sold without brokers, underwriters, or finder fees.
QHSLab also noted it issued a press release on December 29, 2025 titled “QHSLab, Inc. (OTCQB:USAQ) Completes $500K Private Placement, Enters 2026 With Clean Capital Structure,” which was furnished as an exhibit.
QHSLab, Inc. reported that it has launched a new product called Q-Cog™, described as supporting early detection of mild cognitive impairment and dementia. The company disclosed this by issuing a press release titled “QHSLab (OTCQB:USAQ) Announces Launch of Q-Cog™ to Support Early Detection of Mild Cognitive Impairment and Dementia,” which is furnished as an exhibit to this report under a Regulation FD disclosure item.
The company states that the press release is furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporation into other filings unless specifically referenced. QHSLab also highlights that it uses its website and social media channels, along with press releases, to share information that could be considered important for investors.
QHSLab, Inc. filed a Form 8-K to announce that it has made its December 2025 corporate presentation available to the public. The presentation, dated December 1, 2025, provides information about the company’s business and operations and is included as Exhibit 99.1.
The disclosure is made under Regulation FD, which is intended to ensure that important company information is shared broadly and not selectively. QHSLab states that the information in this report and the exhibit is being furnished, not filed, meaning it is not subject to certain liability provisions. The company also highlights that investors and others can access potentially material information through its website, press releases, and social media channels, including Twitter, LinkedIn, Facebook, and Instagram.
QHSLab, Inc. (USAQ) filed an 8-K to furnish a shareholder letter under Regulation FD. On November 24, 2025, the company reported that it sent a letter to its shareholders, which is attached as Exhibit 99.1. The information in this exhibit is furnished under Item 7.01, meaning it is not considered “filed” for liability purposes under Section 18 of the Exchange Act and is not automatically incorporated into other SEC filings unless specifically referenced.
The company reiterates that it has no obligation to update forward-looking statements. It also highlights that investors, media, and others may receive material information through its website (usaqcorp.com), press releases, and social media channels, including Twitter, LinkedIn, Facebook, and Instagram.
QHSLab, Inc. (USAQ) entered into a Note Repurchase Agreement on November 18, 2025 to buy back its outstanding defaulted convertible promissory notes. These notes, issued in 2021 and 2022, had an aggregate outstanding balance of principal and accrued interest in excess of $1.4 million and carried a default interest rate of 18 percent per annum. QHSLab repurchased the notes for a cash payment of $300,000, funded by operating cash and a short-term advance from its President and CEO. Following payment, the notes were fully cancelled, all related liens and obligations were terminated, and all conversion rights, including conversion into common stock at $0.20 per share, were eliminated. The company highlighted this transaction in a press release describing the completion of the repurchase of legacy debt and its impact on the capital structure.
QHSLab, Inc. (USAQ) entered into a Note Repurchase Agreement on November 18, 2025 to buy back its outstanding defaulted convertible promissory notes. These notes, issued in 2021 and 2022, had an aggregate outstanding balance of principal and accrued interest in excess of $1.4 million and carried a default interest rate of 18 percent per annum. QHSLab repurchased the notes for a cash payment of $300,000, funded by operating cash and a short-term advance from its President and CEO. Following payment, the notes were fully cancelled, all related liens and obligations were terminated, and all conversion rights, including conversion into common stock at $0.20 per share, were eliminated. The company highlighted this transaction in a press release describing the completion of the repurchase of legacy debt and its impact on the capital structure.